Reimagining the future of GI cancer care. Bringing together leading experts in the field, this session explored the evaluation of GI malignancies, evolving treatment strategies for hepatocellular carcinoma (HCC), advances in gastric and biliary tract cancers, and multidisciplinary management of rectal cancer. An engaging exchange of clinical insights, emerging evidence, and expert perspectives shaping the future of GI oncology. #GICancer #HCC #GastricCancer #BiliaryTractCancer #RectalCancer #Oncosphere2 #OncologyUpdates #Raipur #OncologyConference #RamkrishnaCareHospitals #CancerCare

An intriguing concept from @BJSurgery. Could metabolic optimization become part of rectal cancer treatment? Total neoadjuvant therapy (TNT) has become the standard of care for locally advanced rectal cancer following landmark trials such as RAPIDO, PRODIGE 23, and OPRA, improving pathological complete response rates, treatment compliance, and disease-free survival. At the same time, GLP-1 receptor agonists have expanded far beyond diabetes and obesity, with emerging evidence suggesting potential anticancer effects. Against this backdrop, a recent BJS review explores the rationale for combining GLP-1 therapy (such as semaglutide) with TNT and highlights a planned phase II randomized trial (NCT07314528). Potential advantages include: • Reduced visceral adiposity • Improved insulin sensitivity • Lower systemic inflammation • Enhanced treatment tolerance Yet an important paradox remains: GLP-1-induced weight loss includes loss of lean muscle mass, and sarcopenia is independently associated with increased treatment toxicity and worse oncologic outcomes in rectal cancer patients undergoing neoadjuvant therapy. The critical question is not whether patients lose weight, but what kind of weight they lose. Can the metabolic benefits of GLP-1 therapy outweigh the risks of skeletal muscle depletion during TNT? This study represents the emergence of “metabolic oncology,” the concept that modulating host metabolism may enhance cancer treatment beyond direct antineoplastic effects. The biological rationale is compelling, but prospective evidence is essential. Critical to the trial’s success will be careful body composition analysis, distinguishing potentially beneficial visceral fat loss from potentially harmful skeletal muscle loss. If positive, this trial could open an entirely new dimension in rectal cancer management. I’d be interested in hearing colleagues’ perspectives on the balance between metabolic optimization and sarcopenia risk during TNT. @SWexner @GaertnerWB @SeanLangenfeld @juliomayol #RectalCancer #ColorectalSurgery #GIOncology #GLP1 #Semaglutide #CancerResearch @ASCRS_1 @AmCollSurgeons @AmColSurgCancer @asgbi @BJSAcademy

Another encouraging outcome highlighting the potential of repurposed-drug-based cancer protocols.#HealthInnovation #CancerSupport #RectalCancer #Oncology #HopeForCancerPatients #DrGeorgeMarkProtocol #MedicalInnovation

🤖 Robotic vs laparoscopic TME for mid/low rectal cancer. Randomised trials only this time — 4 RCTs, 1,952 patients. The pathology favours robotics: 📉 CRM positivity down (OR 0.58), complete mesorectum up (OR 1.55), conversion down (OR 0.41). Early morbidity: no difference. And the part to watch — 2 trials with 3-year data: 📉 lower locoregional recurrence (OR 0.43), a slight DFS edge (HR 0.78). OS unchanged. Robotics doesn't change survival, but it makes a hard operation more reproducibly complete — and the oncology signal is finally starting to show. doi.org/10.1007/s11701-026-0… #RoboticSurgery #RectalCancer

🔪 #2 - TESAR: adjuvant chemoRT vs completion TME after local excision of early rectal cancer (Phase 3, Lancet Gastro Hep) • High-risk pT1 / low-risk pT2, n=197, 25 NL FR centers • 3-yr local recurrence 5.0% vs 1.1% - non-inferiority NOT met • But unsalvageable recurrence 1.3%, OS identical (98.9%) • Stoma rate 2.6% vs 45.4% (p<0.0001) Fails the stats, wins the patient conversation. cTME-as-default deserves rethinking. #ColorectalCancer #RectalCancer #GIOnc doi.org/10.1016/S2468-1253(2…

Application deadline extended ⏳ The new deadline is 10 July! Two intensive days of personalised coaching from leading surgeons and oncologists to: ✅ Refine your technique with high-fidelity hands-on training ✅ Understand emerging paradigms like organ preservation and quality-of-life-centred care ✅ Strengthen knowledge of multimodal treatment strategies This is the ESO Advanced Hands-On Course on #RectalCancer Management. 📍@imperialcollege, London, UK, 27-28 November 2026 Endorsed by @ESSOnews. Learn more 👉🏼 bit.ly/Rectalcancer

#ONCOMETABOLOGY #RectalCancer #BladderCancer #OrganPreservation #ctDNA "Rectum and Bladder: When Organ Preservation Becomes Reality" linkedin.com/posts/gianpaolo…

#RectalCancer symptoms like blood in stools, changes in bowel habits, or unexplained weight loss should never be ignored. Early #CancerDetection and timely #ColorectalCare can save lives. #RectalCancer #CancerDetection #ColorectalCare #EarlyDiagnosis #CancerAwareness

#mdpijcm 🩺Don't miss this #Review #MinimallyInvasiveRectalSurgery: Current Status and Future Perspectives in the Era of Digital Surgery 👉mdpi.com/3180764 ✍️@Gae_Gallo 🏫@SapienzaRoma @MediPharma_MDPI #inflammatoryboweldiseases #rectalcancer #roboticsurgery

#AudioVisualAbstract : The Impact of RAS/BRAF Mutation on Pathological Complete Response After Total Neoadjuvant Therapy in #RectalCancer @Ibrahim_Gomaa95 @DrDavidLarson ow.ly/Jljp50Z8XAj @docgovind @SyedAAhmad5

It may be Cancer Rectum ! Don't treat yourself Medicine in one minute. #rectalcancer #cancerawareness #colorectalcancer #cancersurvivor #jsr #medicineinoneminute

TESAR Trial: Adjuvant ChemoRT vs Completion TME in Early Rectal Cancer TESAR did not formally confirm non-inferiority for 3-year locoregional recurrence. However, adjuvant chemoRT showed low unsalvageable recurrence, fewer stomas, and lower treatment burden. @laura_moolenaar @TBuffart @QDenost @pgdoornebosch @PvanDuijvendijk @JeroenLeijtens @koenpeeters @VdonkTweet @RonaldVuylsteke @BarbaraBastia @marceldijkgraaf oncodaily.com/oncolibrary/ga… #RectalCancer #GIOncology #Oncology

Evaluating the impact of GLP-1 receptor agonists in combination with total neoadjuvant therapy for locally advanced rectal cancer ➡️ doi.org/10.1093/bjs/znag029 🧬 TNT has reshaped the treatment of locally advanced rectal cancer, improving response and long-term outcomes ⚖️ GLP-1 receptor agonists may go beyond weight loss, targeting visceral adiposity, insulin resistance and systemic inflammation 🔥 By modulating host metabolism and tumour biology, GLP-1 RAs could potentially enhance treatment response, tolerance and surgical fitness 🔬 Evidence is still emerging, but this is a promising field for future rectal cancer research Work by Hugo C Temperley , Matthew Coalter , Ben Creavin , Patrick Jordan , Andrew Hogan , Jacintha O’Sullivan , Donal O’Shea , Paul H McCormick , Emily Harrold , Michael E Kelly #RectalCancer #TNT #GLP1 #ColorectalSurgery #CancerResearch #SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @BJSAcademy @young_bjs @BJSOpen @evanscolorectal @robhinchliffe1 @bplwijn @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol @ksoreide

A proud milestone for Fortis Hospital, Manesar, Gurugram. Under the expertise of Dr. Vinay Samuel Gaikwad, the team successfully performed India’s first procedure using the ALPI Tube Faecal Diversion System, an innovative advancement that supports improved recovery for rectal cancer patients. This achievement reflects our continued commitment to delivering advanced, patient-centric cancer care. #FortisHospital #FortisManesar #CancerCare #SurgicalOncology #HealthcareInnovation #MedicalExcellence #RectalCancer #Oncology #AdvancedCare #PatientCare #HealthcareExcellence #MilestoneAchievement

ರೆಕ್ಟಲ್‌ ಕ್ಯಾನ್ಸರ್‌ನಿಂದ ಬಳಲುತ್ತಿರುವ ಅಭಿಮಾನಿ ಆರೋಗ್ಯ ವಿಚಾರಿಸಿದ ನಟ ಯಶ್‌ – ವೀಡಿಯೋ ಕಾಲ್‌ ಮಾಡಿ ಅಭಿಮಾನಿಗೆ ಧೈರ್ಯ ಹೇಳಿದ ಕೆಜಿಎಫ್‌ ಸ್ಟಾರ್‌ publictv.in/kgf-star-yash-vi… #ActorYash #YashFan #KGF #Shivamogga #RectalCancer

Sad to hear of the passing of Dr.Angelita Habr Gama. She was an icon & impacted the lives of so many rectal cancer patients. Thanks to her pioneering work & that of others who followed in her footsteps, we have Watch & Wait as an option for #rectalcancer! RIP Dr. Habr Gama #crcsm

Prof. Angelita Habr-Gama was an absolute titan. It is hard to overstate the profound impact she had on surgical oncology. Before her pioneering work on the "Watch and Wait" approach, radical, life-altering surgery was the unquestioned standard for rectal cancer. It took immense courage, clinical brilliance, and fierce determination to challenge the established dogma of the time. Because she stood her ground and proved what was possible, countless patients worldwide were spared major surgery and given a vastly better quality of life. She didn't just change guidelines; she changed the very philosophy of how we approach rectal cancer treatment, blending rigorous science with deep humanity. As the global colorectal community—including the @TKRCD_ , @ASCRS_1, @escp_tweets @ISUCRS1 @ACPGBI, and @PortalSBCP mourns her passing, her legacy remains alive in every multidisciplinary team discussion, every organ-preserving protocol, and every young surgeon inspired by her pathbreaking career. A truly monumental loss, but an enduring legacy. May she rest in peace. #SoMe4Surgery #AngelitaHabrGama #ColorectalSurgery #RectalCancer #ColorectalCancer #SurgicalOncology #Coloproctology #GlobalSurgery #WomenInSurgery

🕊️ In Memoriam It is with profound sadness that we learned of the passing of Prof. Dr. Angelita Habr-Gama, one of the most influential figures in colorectal surgery and a pioneer whose innovative contributions transformed the treatment of rectal cancer worldwide. Throughout her distinguished career, Prof. Dr. Habr-Gama inspired generations of surgeons and researchers through her dedication to science, education, and patient care. Her pioneering work, particularly in the development of the “watch and wait” approach for rectal cancer, has left a lasting impact on modern surgical practice. We extend our deepest condolences to her family, colleagues, students, and the global colorectal surgery community. Her legacy and contributions to medicine will continue to inspire future generations. Turkish Society of Colon and Rectal Surgery #AngelitaHabrGama #ColorectalSurgery #RectalCancer #WatchAndWait #TSCRS

I just learned #cancer #surgical icon of the #nonoperativemanagement approach to #rectalcancer Dr. Angelita Habr-Gama just passed away today at the age of 93. She was AMAZING! She has changed our views on the necessity of surgery in the setting of cCR. #groundbreaking #cancerresearch #originaldisruptor